Recent content by jondoeuk

Unlike oral finasteride or dutasteride, which reduce systemic DHT levels, pyrilutamide is designed to work locally with a different mechanism of action, so is a good option for those that can't or won't take finasteride or dutasteride. Pyrilutamide 1.0% BID (twice daily): +15.33 hairs/cm² from...

It is critical to distinguish between a drug losing all efficacy and a drug peaking and stabilising. According to top-line data from Kintor's year-long study, patients using 0.5% pyrilutamide twice daily still experienced significant increases in target area hair count (TAHC) and hair width...

Yes. (2026-03-18) ''In terms of efficacy: compared to the placebo group, both 1.0% BID (i.e. twice a day) group and 0.5% BID group demonstrated statistically significant therapeutic efficacy and clinical significance. The target area non-vellus hair counts (“TAHC”) of the 1.0% BID group showed...

New PP405 Phase 2/3 https://clinicaltrials.gov/study/NCT07819435 Estimated start date of Sept 2026. Primary completion date of Dec 2027. Estimated enrolment of 600. All the locations are yet to be declared. Among the inclusion criteria, the one that stands out is: ''Have a modified...

You brought up ''drug resistance'' and all I said was that in individuals who have exceptionally high systemic or localised scalp DHT levels, the available dose of pyrilutamide may simply be overwhelmed (as it physically must outcompete the DHT molecules already present in the scalp). In these...

The second phase III clinical trial was successful. Per Kintor, pyrilutamide has entered the new drug application stage in China. If the application is successful with Chinese regulators (similar to the US FDA and EU EMA), the company expects that it will reach commercialisation in 2027...

Yes. In preclinical binding assays, pyrilutamide demonstrates significantly higher potency than other prominent androgen receptor antagonists. Pyrilutamide has an IC50 value of 0.28 nM, which reflects an exceptionally high binding affinity for the receptor, compared to others like RU58841 (~1.1...

RU58841 has no published clinical safety or efficacy data in humans. Because both RU58841 and pyrilutamide are competitive blockers, they must physically outcompete the DHT molecules already present in the scalp. If an individual has exceptionally high systemic or localised scalp DHT levels...

The half-life is approximately 6–8 hours.

The numbers show statistically significant and clinically meaningful hair growth outcomes, while demonstrating excellent safety. A total of 666 patients were treated for 24 weeks. Both the 1.0% BID (i.e. twice a day) group and 0.5% BID group demonstrated statistically significant therapeutic...

Triple Hair (Canada) began Phase 3 clinical trials for its Therapy-07 (THO7) topical in Vancouver, Canada, It contains minoxidil, finasteride and latanoprost. This product is already available for sale via prescription. However, in August, Triple Hair released an updated pipeline on its...

See my reply to coco_304

Pyrilutamide (KX-826) is sold directly to consumers as a cosmetic under the brand name Koshine ahead of completing approval. You can buy it here https://www.koshinemall.com?sca_ref=7290283.HUfjZVF7fCV5W

Per Kintor's latest pipeline page modification, pyrilutamide has entered the new drug application stage in China. If the application is successful with Chinese regulators (similar to the US FDA and EU EMA), the company expects that it will reach commercialisation in 2027. Pyrilutamide is a...

Kintor plans to initiate the phase IIb/III clinical trial of GT20029 for male androgenetic alopecia in China this year.